Rallybio Declares Estimated $82.7 Million Special Cash Distribution
Rallybio announced an estimated $82.7M special cash distribution, around $13.56 per share, tied to its proposed merger with Avenzo Therapeutics. The final amount may vary and will be paid on November 13, 2026, pending shareholder approval. The record date is expected to be November 5, with the ex-dividend date set for November 6.
How this was made
The 30-second read
Why it matters
The distribution reduces the company's cash reserves and may cause a price adjustment on the ex‑distribution date; investors may trade on the news ahead of the record date.
Market read
Primary disclosure of a material cash distribution for a micro‑cap biotech, offering a clear short‑term trading catalyst.
What to watch
Potential tax implications for shareholders and the impact of the pending merger on future cash flow.
Background
Rallybio Corp (RLYB) filed an 8‑K on Oct 26, 2026 announcing a special cash distribution of approximately $13.56 per share, scheduled for Nov 13, 2026, contingent on shareholder approval of its merger with Avenzo Therapeutics.
Ticker impact
Rallybio announced an $82.7 million special cash distribution linked to its merger with Avenzo Therapeutics.
likely downward pressure as investors price in the cash outflow
Special cash distributions typically lead to a share price adjustment on the ex‑distribution date; the announced amount is material for a micro‑cap biotech.
Market effects
May signal consolidation activity in the biotech sector as merger proceeds.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance beyond biotech M&A watchers.
Counterpoint
Some investors may view the distribution as a sign of limited growth prospects and short the stock.
Key entities
- CompanyRallybio Corp
Biotech firm merging with Avenzo Therapeutics.
- CompanyAvenzo Therapeutics
Merger partner of Rallybio.
